Every 10-Q that VICARIOUS SRGCL INC A (RBOT) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow RBOT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RBOT filings page.
Vicarious Surgical Inc. reported a Q1 2026 net loss of $7,329k with no revenue as it continues developing its surgical robotic system. Operating expenses fell 52% year over year to $7,502k, driven by a roughly 60%+ reduction in headcount and lower R&D, sales and administrative spending.
Cash, cash equivalents and short-term investments totaled $3,682k as of March 31, 2026, and management states this is only expected to fund operations through the second quarter of 2026. The filing explicitly notes substantial doubt about the company’s ability to continue as a going concern unless it raises additional capital.
On March 3, 2026, the NYSE suspended trading and began delisting proceedings for the Class A common stock after the company fell below the exchange’s market capitalization standard; shares now trade on the OTCQB under “RBOT,” and the company is seeking a Nasdaq listing and has stockholder approval for a potential reverse stock split.
Vicarious Surgical (RBOT) filed its Q3 2025 10‑Q and flagged liquidity risk. The company reported a Q3 net loss of $11,058,000, with total operating expenses of $11,503,000 (down 35% year over year). For the nine months ended September 30, 2025, net loss was $39,667,000 and net cash used in operating activities was $35,764,000.
Cash, cash equivalents and short‑term investments were $13,414,000 as of September 30, 2025. The company received approximately $5,200,000 in net proceeds from an October 2025 registered direct offering. Management states this raises substantial doubt about continuing as a going concern and currently expects resources to support operations into the first quarter of 2026.
The company remains pre‑revenue and continues R&D on its single‑port surgical robot, noting controlled builds in April 2025 and August 2025. Vicarious also disclosed prior NYSE noncompliance with the $50,000,000 market cap/equity standard; the exchange accepted its remediation plan, and the stock continues to trade during the cure period.
Vicarious Surgical Inc. remains pre-revenue and reported a six-month net loss of $28.6 million and a three-month net loss of $13.2 million. Total assets declined to $40.9 million from $67.7 million, driven by lower cash and short-term investments. Cash and cash equivalents were $3.9 million and short-term investments were $20.1 million, totaling $23.96 million at June 30, 2025.
Management disclosed that these funds are insufficient to support operations for the next 12 months, raising substantial doubt about the company's ability to continue as a going concern and requiring pursuit of additional equity or debt financing. The company reduced operating expenses year-over-year (R&D, G&A and S&M), improving loss from operations by ~13% for the six-month comparison. The NYSE notified the company of non-compliance with market capitalization standards but accepted the company’s cure plan for the specified review period. A CEO appointment was announced as a subsequent event.